URGN Q1 2021 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M

Gross Profit

$7M88.0% margin

Operating Income

-$26M-348.9% margin

Net Income

-$26M-346.5% margin

EPS (Diluted)

$-1.17

QoQ Revenue Growth

-6.0%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$97M

Total Liabilities

$21M

Stockholders' Equity

$76M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$0	—
Gross Profit	$7M	$0	—
Operating Income	-$26M	-$39M	+32.3%
Net Income	-$26M	-$38M	+31.4%